Over 90 Total Lots Up For Auction at One Location - WA 04/08

iCAD announces ProFound AI Risk for 3D mammography

Press releases may be edited for formatting or style | September 30, 2021 Artificial Intelligence Women's Health
NASHUA, N.H. – September 29, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, as well as an updated version of PowerLook® Density Assessment. Both technologies offer improved accuracy and enhanced functionality compared to previous versions of the software.

ProFound AI Risk is the world's first commercially available clinical decision support tool that provides an accurate[1],[2] short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. The latest generation of PowerLook Density Assessment is the world's first and only multi-vendor deep learning automated breast density assessment algorithm using synthetic images generated from 3D mammography.1,[3]

"ProFound AI Risk and PowerLook Density Assessment have the potential to truly transform personalized breast cancer screening and risk stratification as we know it," said Stacey Stevens, President of iCAD, inc. "We believe these technologies will lead to more appropriate utilization of supplemental imaging and biopsies, less anxiety for women, and decreased costs to the system overall. We believe these solutions will be increasingly relevant in the years ahead, as mammography begins to transition from what is primarily an age-based screening paradigm today to a more effective and efficient risk-adjusted screening paradigm."

The latest generation of ProFound AI Risk offers the ability to calculate a short-term risk estimation for 3D mammography, with greater accuracy compared to both the previous version of the risk software based on 2D mammography and traditionally used risk models. The latest version of ProFound AI Risk offers expanded features, including:

- The ability to calculate short-term (one-, two- or three-year) absolute risk based on either 2D or 3D mammography images.

- The ability to factor in clinically relevant global screening guidelines and more than 15 country incidence and mortality reference tables, including ethnicities, for alignment with that country's general population.

"Factoring in a woman's racial and ethnic background adds another dimension of personalization that allows clinicians to stratify risk in a more inclusive way," added Stevens. "Studies show African American women have an approximately 40% higher risk of dying from breast cancer, and they are disproportionately affected by more aggressive subtypes, such as triple-negative breast cancer and inflammatory breast cancer, compared to white women. The latest generation of ProFound AI Risk offers the potential to address these racial disparities and improve outcomes for women, including those who may have higher risks of developing cancers between screenings due to genetic predispositions."

You Must Be Logged In To Post A Comment